Tabletting, coating & ancillary equipment

German lyophilisation ramp-up could be delayed into next year, Recipharm

31-Jul-2017 By Dan Stanton

A lyophilisation expansion announced in 2013 at an aseptic facility in Wasserburg, Germany has been delayed due to lengthy approval processes, says Recipharm.

TPI Enterprises buys Vistin opiates assets and confirms Portugal plant plan

21-Jul-2017 By Gareth Macdonald

TPI Enterprises has bought Vistin Pharma ASA’s opiates and tabletting division for A$25.4m ($201.m) in a deal designed to expand the firm beyond its narcotic raw materials business.

Idifarma adds contract capsule filling to offering

18-Jul-2017 By Staff Reporter

Idifarma has bolstered its capsule filling capabilities at its manufacturing plant in Pamplona, Spain.

Bayer ends methamphetamine abuse deterrent partnership with Acura

06-Jul-2017 By Dan Stanton

Bayer has pulled-out of a development and licensing deal for a pseudoephedrine containing product based on Acura Pharmaceuticals’ methamphetamine resistant technology, Impede.

Corning life science focus: '21st century glass for 21st century drugs'

21-Jun-2017 By Dan Stanton

Corning says it is on the brink of capturing an increased share of the $12bn glass quality and packaging markets through material advancements in the space.

Takeda inaugurates €100m German oral solid dose plant

20-Jun-2017 By Staff Reporter

Takeda has completed a €100m ($112m) oral solid dosage production facility in Germany.

'Talking' smart pill looks to overhaul prescription opioid space and stop abuse

08-Jun-2017 By Dan Stanton

Pop Test Abuse Deterrent Technologies has received a patent for an opioid drug delivery and abuse deterrent ‘smart pill’ it says can prevent death, theft, diversion and counterfeiting.

Vetter inks ‘pain-free’ needle deal to meet alternative drug delivery demand

05-Jun-2017 By Flora Southey

Vetter Pharma has signed a strategic agreement to develop Microdermics’ microneedle drug delivery technology.

Valium blister pack tampering leads to Australian recall for Roche and Apotex

01-Jun-2017 By Dan Stanton

Roche has recalled all batches of Valium 5mg tablets in Australia after finding evidence of product tampering within its supply chain.

CDMO Recro expands manufacturing capabilities at former Alkermes site

24-May-2017 By Melissa Fassbender

Recro has added a new tablet manufacturing suite that enables it to compress single- and bi-layer tablets at commercial speeds.

Coming to America: Evolving pharma landscape brings CPhI to Philadelphia

16-May-2017 By Dan Stanton

With almost 40% of attendees coming from outside the US, the political climate has had no effect on the latest CPhI franchise which starts today in Philadelphia.

H&T Presspart buys rights to Hovione inhaler tech

27-Apr-2017 By Staff Reporter

H&T Presspart has bought the rights to manufacture and commercialise a capsule-based dry powder inhaler (DPI) from Hovione.

DISPATCHES FROM BPI EUROPE 2017

Messenger RNA a ‘game-changer’ for vaccine industry, Sanofi Pasteur

26-Apr-2017 By Dan Stanton

Sanofi Pasteur says heavy investment in messenger RNA (mRNA) is warranted as such technology could revolutionise vaccine development and manufacturing.

Compounding firm looks at NDA opportunity for reformulation of Mallinckrodt's H.P. Acthar

23-Mar-2017 By Dan Stanton

Imprimis Pharmaceuticals says it is evaluating pursuing New Drug Application (NDA) status for some of its product reformulations through the US FDA 505(b)(2) development pathway.

Keryx: Patheon and Norwich sites will ensure supply of iron-based Auryxia

06-Mar-2017 By Dan Stanton

Keryx Biopharmaceuticals will continue to work with Norwich Pharmaceuticals despite bringing Patheon on board to manufacture Auryxia (ferric citrate).

Turmeric bioavailability enhancer could be used with APIs, Wacker

02-Mar-2017 By Staff Reporter

Wacker Biosolutions says an excipient shown to increase the bioavailability of a food supplement by a factor of 40 could have implications in the API space.

Allergan's €42m investment boosts Irish manufacturing and jobs

02-Mar-2017 By Dan Stanton

Allergan has committed €42m ($44m) to increase capacity and capabilities at two manufacturing facilities in Ireland.

Cardboard and brown agglomerates: FDA slams Pfizer injectables plant

01-Mar-2017 By Dan Stanton

Particulate problems in sterile injectables and poor aseptic techniques landed Pfizer with a US FDA warning letter at a former Hospira facility in Kansas.

Baxter and ScinoPharm sign injectable oncology drug strategic alliance

01-Mar-2017 By Dan Stanton

Up to 20 injectable cancer drugs will be made at facilities in Taiwan and Germany under terms of a partnership between Baxter and Scinopharm.

Pfizer hit with US FDA warning at Kansas generic Copaxone site

20-Feb-2017 By Dan Stanton

The US FDA has issued a warning letter to the former Hospira fill and finish facility in McPherson, Kansas – now part of Pfizer’s contract manufacturing business CentreOne.

Is the return of the one-stop-shop model just a CMO marketing ploy?

16-Feb-2017 By Dan Stanton

End-to end service offerings are a differentiator within the fragmented CMO industry and not driven by pharma demand, a Results Healthcare report says.

Quotient buys QS Pharma in latest US expansion move

15-Feb-2017 By Dani Bancroft

Quotient Clinical Ltd. has bought Charles River Laboratories’ contract manufacturing business, QS Pharma LLC.

GSK on America First: US will not be able to own every part of supply chain

13-Feb-2017 By Dan Stanton

GSK has warned that Donald Trump’s plan to encourage US drug production through import tax hikes must take the global nature of pharma supply chains into account.

Ferring licenses Enteris Peptelligence to turn injectable into oral drug

30-Jan-2017 By Dani Bancroft

Ferring is the third company in a week which will use Enteris BioPharma’s Peptelligence engineering platform for small molecules to develop oral formulations.

Improving solubility: MilliporeSigma opens dedicated meglumine site

19-Jan-2017 By Dan Stanton

MilliporeSigma has opened a facility in Spain dedicated to the manufacture of the solubility-enhancing excipient meglumine.

Catalent to assess resveratrol formulation across softgel platforms

11-Jan-2017 By Dan Stanton

Catalent will assess Jupiter Orphan Therapeutics’ resveratrol across its softgel technologies in an effort to improve the bioavailability of the rare disease candidate.

T-ray technique faster for tablet quality and structure testing say researchers

11-Jan-2017 By Gareth Macdonald

High frequency radiation can be used to test tablet quality and structural characteristics on the production line according to scientists planning to develop low cost THz sensors. 

US DEA finalises controlled substance and equipment revisions

09-Jan-2017 By Dan Stanton

Drugmakers must include a transaction identification number when buying or selling machinery for tabletting or encapsulating controlled substances, according to a final ruling from the US DEA.

Spain's Idifarma adds capsule filling to service offerings

01-Dec-2016 By Dan Stanton

Idifarma has invested over €300,000 in its facility in Spain in order to offer its customers automated capsule filling for commercial batches.

Catalent adding OTC capsule maker Accucaps to global softgel network

28-Nov-2016 By Dan Stanton

Catalent will add two Canadian manufacturing facilities to its softgel network through the acquisition of Accucaps.

Evonik to construct second Alabama facility for drug delivery polymers

23-Nov-2016 By Dan Stanton

Evonik has laid plans to expand a polymer facility in Alabama to cater for growing demand for sophisticated drug delivery and medical devices.

Sanofi insulin buy back and rival price hikes a boon for MannKind's Afrezza

14-Nov-2016 By Dan Stanton

Despite requiring more API, the price of inhaled insulin Afrezza has dropped below that of injected rapid-acting rivals says MannKind's CEO, reporting a resilient Q3.

Slovakian CDMO Saneca ups capabilities after controlled release contract win

10-Nov-2016 By Staff Reporter

Saneca Pharma will invest in its manufacturing site in Slovakia to service a five-year agreement supplying the Menarini Group with controlled release pellets.

GSK exiting Australian OTC site: over 200 jobs to be lost

07-Nov-2016 By Dan Stanton

GSK says it remains dedicated to Australian despite announcing plans to shutter a painkiller manufacturing site in Sydney.

Datwyler injects CHF 100m into US drug delivery component site

03-Nov-2016 By Staff Reporter

Increasing demand for reduced particle loads in pharmaceutical containers has driven Datwyler to build a CHF 100m plant making elastomer components for injectable drug delivery systems.

Everstone Capital buys stake in Rubicon Research citing delivery techs and ANDAs

25-Oct-2016 By Staff Reporter

Everstone Capital has acquired a 70% stake in drug delivery tech firm Rubicon Research Pvt for $33m (€30m).

Roller compactor bolsters Juniper's granulation capabilities

17-Oct-2016 By Staff Reporter

CDMO Juniper Pharma Services has added a small-scale roller compactor as the latest investment in its enabling technology offerings.

Aralez buys rights to AZ heart drug; encouraged by generic quality issues

10-Oct-2016 By Dan Stanton

AstraZeneca will supply Toprol-XL to Aralez Pharmaceuticals Trading for at least 10 years after selling the US rights to the off-patent beta blocker for $175m.

Dispatches from CPhI Worldwide 2016

Capsugel: enteric polymer comprising tech can speed-up drug development

04-Oct-2016 By Dan Stanton

Capsugel’s Vcaps Enteric offering can speed up development of delayed release drugs by removing the need for an additional enteric film coat, the firm says.

US FDA: Cheng Fong Chemical must do more to investigate complaints

28-Sep-2016 By Gareth Macdonald

Cheng Fong Chemical has addressed problems at its Taoyuan City plant but still needs to identify the source of foreign matter found in its APIs according to the US FDA.

BD injects $100m into Nebraska insulin syringe plant

27-Sep-2016 By Dan Stanton

Becton Dickinson says it is upgrading equipment and technology at its Holdrege manufacturing facility to better serve the global diabetes market.

US FDA warns against $30 DIY alternative to Mylan's EpiPen

22-Sep-2016 By Dan Stanton

The US FDA has warned people not to use a $30 DIY epinephrine delivery device developed after Mylan increased the price of the Epipen.

Colorcon and Dow extend controlled release alliance

22-Sep-2016 By Staff Reporter

Colorcon and Dow have expanded a nine year controlled release alliance to include further solubility, coating and ion exchange platforms.

Sartorius pledges to cut development times with upstream suite

22-Sep-2016 By Phil Taylor

Sartorius Stedim Biotech claims it has a platform that can help biopharma companies carve months off the development time for new products.

Bespak to supply AstraZeneca components for LAMA/LABA inhaler

14-Sep-2016 By Dan Stanton

AstraZeneca has struck a supply deal with Bespak for components in pressurised metered-dose inhalers (pMDIs) for a recently approved COPD treatment. 

Spain's Idifarma bolstered by investment from API maker Suanfarma

12-Sep-2016 By Dan Stanton

Spanish API maker Suanfarma has acquired a stake in contract manufacturer and spray-drying specialist Idifarma, boosting its international presence.

Chemical fast-track could speed up nitrile drug synthesis

06-Sep-2016 By Phil Taylor

A synthetic short cut could make it easier and cheaper to produce nitrile-containing compounds, a group which includes dozens of marketed and pipeline drugs.

Recipharm inks manufacturing and controlled release tech deal with Tillotts

01-Sep-2016 By Dan Stanton

Recipharma will provide pellet coating technology for controlled release drugs to Tillotts Pharma as part of a long-term manufacturing deal.

Flexible molecules could be better drugs - for some targets

31-Aug-2016 By Phil Taylor

For drug molecules, having a flexible rather than a rigid structure can sometimes make you a better medicine, say scientists in California.

Mylan price hikes: Congress calls on FDA for generic EpiPen submission info

30-Aug-2016 By Dan Stanton

Congress has asked the US FDA for information on EpiPen generic submissions and processes in light of a series of price hikes by drugmaker Mylan.